Mouse Models for Immune Checkpoint Blockade Therapeutic Research in Oral Cancer.
Wei-Chiao ChiuDa-Liang OuChing-Ting TanPublished in: International journal of molecular sciences (2022)
The most prevalent oral cancer globally is oral squamous cell carcinoma (OSCC). The invasion of adjacent bones and the metastasis to regional lymph nodes often lead to poor prognoses and shortened survival times in patients with OSCC. Encouraging immunotherapeutic responses have been seen with immune checkpoint inhibitors (ICIs); however, these positive responses to monotherapy have been limited to a small subset of patients. Therefore, it is urgent that further investigations into optimizing immunotherapies are conducted. Areas of research include identifying novel immune checkpoints and targets and tailoring treatment programs to meet the needs of individual patients. Furthermore, the advancement of combination therapies against OSCC is also critical. Thus, additional studies are needed to ensure clinical trials are successful. Mice models are advantageous in immunotherapy research with several advantages, such as relatively low costs and high tumor growth success rate. This review paper divided methods for establishing OSCC mouse models into four categories: syngeneic tumor models, chemical carcinogen induction, genetically engineered mouse, and humanized mouse. Each method has advantages and disadvantages that influence its application in OSCC research. This review comprehensively surveys the literature and summarizes the current mouse models used in immunotherapy, their advantages and disadvantages, and details relating to the cell lines for oral cancer growth. This review aims to present evidence and considerations for choosing a suitable model establishment method to investigate the early diagnosis, clinical treatment, and related pathogenesis of OSCC.
Keyphrases
- end stage renal disease
- mouse model
- clinical trial
- ejection fraction
- newly diagnosed
- lymph node
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- combination therapy
- open label
- public health
- patient reported outcomes
- adipose tissue
- skeletal muscle
- replacement therapy
- insulin resistance
- rectal cancer
- free survival